Last reviewed · How we verify

Maintenance of ULT

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

Maintenance of ULT is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development.

At a glance

Generic nameMaintenance of ULT
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Maintenance of ULT

What is Maintenance of ULT?

Maintenance of ULT is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes Maintenance of ULT?

Maintenance of ULT is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is Maintenance of ULT in?

Maintenance of ULT is in Phase 2.

Related